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Mechanisms Behind
Intracoronary Radiation Therapy Failure
We read with great interest the study by Ajani et al., “The
Outcome of Percutaneous Coronary Intervention in Patients With
In-Stent Restenosis Who Failed Intracoronary Radiation Ther-
apy” (1). Limited data are available on the outcomes of patients
with in-stent restenosis (ISR) who undergo treatment using
intracoronary radiation therapy (IRT) and subsequently “fail,” and
the study by Ajani and colleagues provides new data on this
important subject. The investigators reported that the rate of failed
IRT was 29%. This is similar to findings from our institution
where we reported a 15.6% failure rate after IRT for ISR in a broad
range of patients (2). In our study, ostial location and smaller
postprocedural minimal luminal diameter were correlated with
subsequent failure after IRT. Do the investigators of this current
study have information regarding the effects of these factors on
influencing long-term clinical outcomes in their patient cohort?
In this current study, cutting balloon angioplasty (CBA) was
utilized in only 2% of cases after failed IRT. Because of the
potential for minimizing arterial injury, reducing the proliferative
neointimal response, achieving a greater postprocedural minimal
luminal diameter, and decreasing slippage due to “watermelon
seeding,” CBA has been shown to be a safe and feasible strategy for
the treatment of ISR (3); however, the impact of CBA in
combination with IRT for the treatment of ISR has not been well
established. We recently reported data from our institution which
showed that the strategy of CBA and IRT using Sr-90 for ISR was
associated with similar major adverse cardiac events (death, myo-
cardial infarction, and target vessel revascularization) at 6 months
compared to percutaneous transluminal coronary angioplasty
(PTCA) and IRT in 102 consecutive patients (20.0% vs. 29.8%,
p  0.36) (4). Thus, although CBA has the potential of avoiding
geographic miss by limiting the mismatch between the injured and
irradiated arterial segments, it does not appear to offer any clinical
advantage over conventional balloon angioplasty in combination
with IRT, although further studies are needed to clarify this issue.
The mechanism behind this observed lack of benefit for the
treatment of ISR may be that, although CBA appears to increase
neointimal tissue extrusion, intravascular ultrasound studies have
shown that CBA, unlike PTCA, is associated with minimal stent
overexpansion (5).
The majority of the patients in the current study presented with
a focal pattern of restenosis. Did the clinical presentation of these
patients differ from those who presented with diffuse or edge
restenosis?
In the study by Ajani et al. (1), the mean time to first target
vessel revascularization (TVR) was 173  127 days after the index
procedure. Other studies have noted that in patients who “fail”
IRT, treatment with brachytherapy delays the time to the first
TVR (295 206 days) compared to the placebo group (202 167
days) (p  0.03) (6). Preliminary data from our medical center
suggests that up to 25% of patients who ultimately “fail” IRT
present more than eight months after the index treatment, and in
these patients the mean duration to TVR was 14.2  3.7 months
(7). Do the investigators of the current study (1) have data on
patients who failed IRT and who presented beyond the traditional
time period for restenosis (six to nine months)?
Although glycoprotein IIb/IIIa inhibitors (GPI) have been
shown to be beneficial in a wide variety of coronary interventional
procedures, the impact of these agents on improving outcomes in
patients with ISR using IRT is not clearly defined. One study
showed that the utilization of GPI in conjunction with IRT for
ISR was associated with similar death, myocardial infarction, and
TVR compared to IRT without GPI (19.5% vs. 23.7%, p 0.511)
(8). What was the rate of utilization of GPI in the current study,
and did this influence the outcome?
The study by Ajani and co-workers contributes greatly to our
understanding of the issues surrounding the optimal implementa-
tion of IRT in this high-risk population. Assessing the risk for
IRT failure and elucidating the mechanisms underlying these
adverse events will contribute significantly to the application of
IRT for ISR in the drug-eluting stent era.
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We have previously reported that ostial in-stent restenotic lesions
treated with intracoronary radiation have equivalent clinical out-
comes to nonostial irradiated in-stent restenotic lesions and have
significantly reduced recurrent restenosis compared to in-stent
restenotic ostial lesions treated with conventional percutaneous
interevention alone (1). We did not find that postprocedural
minimal luminal diameter correlated with subsequent failure,
although smaller vessels (based on reference vessel diameter) have
higher restenosis rates. Intracoronary radiation therapy reduces
angiographic restenosis in all sized vessels, with the effect seen
predominantly in small vessels (2.5 mm) (2). In the current
analysis, these factors did not influence clinical outcomes.
The initial enthusiasm for the cutting balloon as an interven-
tional strategy for in-stent restenosis has not been supported by
reduced event rates in clinical trials. There is no evidence showing
the cutting balloon to be superior over conventional angioplasty
with adjunctive intracoronary radiation.
Our ongoing analysis suggests the time to first target vessel
revascularization in the majority of patients is between 6 to 12
months, suggesting there is a “delay” in recurrent restenosis
compared to conventional angioplasty. Recurrent restenosis be-
yond 12 months has been infrequent in the majority of published
Washington Radiation for In-stent restenosis Trial (WRIST)
series.
The overall use of glycoprotein (GP) IIb/IIIa inhibitors in the
current analysis was 22% and did not influence clinical outcomes.
Integrilin WRIST was a randomized trial addressing whether the
treatment of eptifibatide (small-molecule competitive GPIIb/IIIa
inhibitor) would improve both the procedural and the long-term
outcomes in patients undergoing treatment for in-stent restenosis
with intracoronary radiation therapy. That study (submitted for
publication) did not detect differences in major clinical events with
use of GPIIb/IIIa inhibitors. However, at any end point of the
study there was nonsignificant reduction of creatine phosphokinase
release in the eptifibatide group when compared to control, and
these findings may stimulate a larger study to detect benefit of










1. Ajani AE, Waksman R, Cheneau E, et al. Impact of intracoronary
radiation on in-stent restenosis involving ostial lesions. Catheter Car-
diovasc Interv 2003;58:175–80.
2. Ajani AE, Waksman R, Kim H-S, et al. The impact of lesion length
and reference vessel diameter on angiographic restenosis and target
vessel revascularization in treating in-stent restenosis with radiation.
J Am Coll Cardiol 2002;39:1290–6.
Clinical Decision Making
on Statin Drug Interactions
Recent comments by Dr. Hansten (1) regarding drug-drug inter-
actions and myopathy risk with statins provide important addi-
tional information to guidelines issued last year on the use of these
agents (2). The metabolism of statins is complex, with extensive
conversion between the lactone, open-acid, and glucuronidated
forms as well as other less common metabolites (3,4). As Dr.
Hansten noted, pravastatin undergoes the least cytochrome P450
(CYP)-mediated metabolism and is therefore the least susceptible
to interactions with drugs that inhibit this system (5–7). Also,
simvastatin and lovastatin are more prone to interactions with
CYP inhibitors, owing in part to the fact that these agents are
administered as the more lipophilic lactone form, whereas all other
agents (including cerivastatin) are administered as the open-acid
form (3,8). And though these findings are important, I believe they
should be incorporated into clinical practice with several important
caveats in mind.
First, the kinetics of statins is more complex than just their
hepatic handling. The 5-fold increase in pravastatin area under the
curve (AUC) induced by cyclosporine is now widely recognized to
be the result of inhibition of the adenosine triphosphate-binding
cassette transporter P-glycoprotein (Pgp) in the gut wall (9,10).
Inhibition of Pgp allows greater absorption of pravastatin, thereby
increasing its systemic bioavailability, which is already four-fold
higher than lovastatin and simvastatin (3,8). Other inhibitors of
Pgp include erythromycin, quinidine, amiodarone, and verapamil
(11–13).
Second, the greatest risk of myopathy with statins occurs when
they are used with other lipid-lowering agents and is the result of
pharmacodynamic, as well as pharmacokinetic, interactions
(3,8,10,14). In this regard, pravastatin carries an increased risk
similar to the other agents (5,15,16). And though case reports of
myopathy are more common with lovastatin and simvastatin, four
published studies of 39,285 patients and over 160,000 patient-
years of therapy have failed to find a greater risk for these agents
compared to placebo (14,17,18).
Finally, the primary aim of statins is to reduce cardiovascular
(CV) events. The recent failure of 40 mg of pravastatin to
significantly reduce CV events in the ALLHAT-LLT trial (19)
stands in contrast to the recent findings of a robust benefit of 40
mg of simvastatin in the HPS trial (17). It is also notable that while
a lower threshold low density lipoprotein (LDL) of 125 mg/dl was
found for the beneficial effects of pravastatin in both the CARE
and LIPID trials (20,21), no such threshold finding for simvastatin
was found in the 4S trial (18). In fact, in the HPS trial, CV events
were significantly reduced by simvastatin in the 3,500 participants
with a baseline LDL below 100 mg/dl (mean 97 mg/dl) (17).
Thus, though interactions should always be considered when
prescribing multiple medications, until clearer mechanisms of both
benefit and risk are elucidated for statins, outcomes data remain
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